Literature DB >> 25883340

Infectious disease. Combating emerging viral threats.

Elena Bekerman1, Shirit Einav2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25883340      PMCID： PMC4419706          DOI： 10.1126/science.aaa3778

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  14 in total

Review 1.  Clinical uses of interferons.

Authors:  Robert M Friedman
Journal:  Br J Clin Pharmacol       Date:  2007-12-07       Impact factor: 4.335

2.  Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

Authors:  Julie Dyall; Christopher M Coleman; Brit J Hart; Thiagarajan Venkataraman; Michael R Holbrook; Jason Kindrachuk; Reed F Johnson; Gene G Olinger; Peter B Jahrling; Monique Laidlaw; Lisa M Johansen; Calli M Lear-Rooney; Pamela J Glass; Lisa E Hensley; Matthew B Frieman
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

3.  Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses.

Authors:  Diana F Florescu; Megan A Keck
Journal:  Expert Rev Anti Infect Ther       Date:  2014-08-13       Impact factor: 5.091

4.  Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells.

Authors:  Stephanie Pollock; Norica Branza Nichita; Annette Böhmer; Cristina Radulescu; Raymond A Dwek; Nicole Zitzmann
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-20       Impact factor: 11.205

5.  Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase.

Authors:  Mayra García; Arik Cooper; Wei Shi; William Bornmann; Ricardo Carrion; Daniel Kalman; Gary J Nabel
Journal:  Sci Transl Med       Date:  2012-02-29       Impact factor: 17.956

6.  Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly.

Authors:  Gregory Neveu; Rina Barouch-Bentov; Amotz Ziv-Av; Doron Gerber; Yves Jacob; Shirit Einav
Journal:  PLoS Pathog       Date:  2012-08-16       Impact factor: 6.823

Review 7.  Animal models, prophylaxis, and therapeutics for arenavirus infections.

Authors:  Eric Vela
Journal:  Viruses       Date:  2012-09-24       Impact factor: 5.048

Review 8.  Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century.

Authors:  Jean-Marc Rolain; Philippe Colson; Didier Raoult
Journal:  Int J Antimicrob Agents       Date:  2007-07-16       Impact factor: 5.283

Review 9.  Nitazoxanide: a first-in-class broad-spectrum antiviral agent.

Authors:  Jean-François Rossignol
Journal:  Antiviral Res       Date:  2014-08-07       Impact factor: 5.970

10.  Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.

Authors:  Travis K Warren; Jay Wells; Rekha G Panchal; Kelly S Stuthman; Nicole L Garza; Sean A Van Tongeren; Lian Dong; Cary J Retterer; Brett P Eaton; Gianluca Pegoraro; Shelley Honnold; Shanta Bantia; Pravin Kotian; Xilin Chen; Brian R Taubenheim; Lisa S Welch; Dena M Minning; Yarlagadda S Babu; William P Sheridan; Sina Bavari
Journal:  Nature       Date:  2014-03-02       Impact factor: 49.962
View more
  81 in total

1.  Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3- b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity.

Authors:  Sven Verdonck; Szu-Yuan Pu; Fiona J Sorrell; Jon M Elkins; Mathy Froeyen; Ling-Jie Gao; Laura I Prugar; Danielle E Dorosky; Jennifer M Brannan; Rina Barouch-Bentov; Stefan Knapp; John M Dye; Piet Herdewijn; Shirit Einav; Steven De Jonghe
Journal:  J Med Chem       Date:  2019-06-12       Impact factor: 7.446

2.  Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.

Authors:  Szu-Yuan Pu; Randy Wouters; Stanford Schor; Jef Rozenski; Rina Barouch-Bentov; Laura I Prugar; Cecilia M O'Brien; Jennifer M Brannan; John M Dye; Piet Herdewijn; Steven De Jonghe; Shirit Einav
Journal:  J Med Chem       Date:  2018-07-16       Impact factor: 7.446

Review 3.  The Role of Host Cytoskeleton in Flavivirus Infection.

Authors:  Yue Zhang; Wei Gao; Jian Li; Weihua Wu; Yaming Jiu
Journal:  Virol Sin       Date:  2019-02-06       Impact factor: 4.327

4.  Zika Virus Dependence on Host Hsp70 Provides a Protective Strategy against Infection and Disease.

Authors:  Shuhei Taguwa; Ming-Te Yeh; T Kelly Rainbolt; Arabinda Nayak; Hao Shao; Jason E Gestwicki; Raul Andino; Judith Frydman
Journal:  Cell Rep       Date:  2019-01-22       Impact factor: 9.423

5.  Inhibition of Human Adenovirus Replication by the Importin α/β1 Nuclear Import Inhibitor Ivermectin.

Authors:  Cason R King; Tanner M Tessier; Mackenzie J Dodge; Jason B Weinberg; Joe S Mymryk
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

6.  Resource fluctuations inhibit the reproduction and virulence of the human parasite Schistosoma mansoni in its snail intermediate host.

Authors:  David J Civitello; Lucy H Baker; Selvaganesh Maduraiveeran; Rachel B Hartman
Journal:  Proc Biol Sci       Date:  2020-01-22       Impact factor: 5.349

7.  Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo.

Authors:  Julia Ma; Xuexiang Zhang; Veronica Soloveva; Travis Warren; Fang Guo; Shuo Wu; Huagang Lu; Jia Guo; Qing Su; Helen Shen; Eric Solon; Mary Ann Comunale; Anand Mehta; Ju-Tao Guo; Sina Bavari; Yanming Du; Timothy M Block; Jinhong Chang
Journal:  Antiviral Res       Date:  2017-12-15       Impact factor: 5.970

8.  Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis.

Authors:  Antonia P Gunesch; Francisco J Zapatero-Belinchón; Lukas Pinkert; Eike Steinmann; Michael P Manns; Gisbert Schneider; Thomas Pietschmann; Mark Brönstrup; Thomas von Hahn
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

Review 9.  Improving therapy of severe infections through drug repurposing of synergistic combinations.

Authors:  Yu-Shan Cheng; Peter R Williamson; Wei Zheng
Journal:  Curr Opin Pharmacol       Date:  2019-08-24       Impact factor: 5.547

10.  Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment.

Authors:  Szu-Yuan Pu; Fei Xiao; Stanford Schor; Elena Bekerman; Fabio Zanini; Rina Barouch-Bentov; Claude M Nagamine; Shirit Einav
Journal:  Antiviral Res       Date:  2018-05-16       Impact factor: 5.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.